Magnetic stimulation to the brain to test walking in Parkinson's disease
Tests magnetic brain stimulation to see whether it helps walking in Parkinson's disease.
Plain-language title generated from the registry record
Registry title: The Effect of rTMS Over the SMA on Gait Performance in Parkinson's Disease
Key facts
- Where
- Kowloon, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT07190235, who can take part
Where in Hong Kong
- The Hong Kong Polytechnic UniversityKowloon, Hong KongNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Hong Kong Polytechnic University
- Trial code
- NCT07190235
- Record updated
- 2 January 2026
- Original description
This study aims to investigate the effects of high-frequency and low-frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) on gait performance, especially gait initiation, in individuals with Parkinson's disease (PD). Furthermore, the investigators will explore the impact of rTMS over the SMA on walking speed, functional mobility, and limits of stability in PD. It is hypothesized that rTMS over the SMA will improve gait performance in PD.Read full original descriptionShow less
The Effect of Repetitive Transcranial Magnetic Stimulation Over the Supplementary Motor Area on Gait Performance in Parkinson's Disease: A Randomized Controlled Trial
This study aims to investigate the effects of high-frequency and low-frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) on gait performance, especially gait initiation, in individuals with Parkinson's disease (PD). Furthermore, the investigators will explore the impact of rTMS over the SMA on walking speed, functional mobility, and limits of stability in PD. It is hypothesized that rTMS over the SMA will improve gait performance in PD.
Inclusion: diagnosed with PD according to thecriteria set by Movement Disorder Committee,; with Hoehn and Yahr stages II-III, which are recognized as representing mild to moderate disease severity,; have self-reported difficulty in gait initiation, assessed by item 5 of the freezing of gait questionnaire (FOGQ),; have used a dopaminergic medication dose in the last month,; a minimum score of 23 of 30 points on the Montreal Cognitive Assessment (MoCA).
Exclusion: patients with unstable medical conditions,; other neurological conditions including stroke,; unable to provide informed consent,; contraindications for TMS,; experienced deep brain stimulation treatment,; no recordable motor evoked potentials (MEPs) with TMS.